Decision: Favourable
Study Title:
An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer
NREC Code:
22-NREC-CT-116
Decision:
Favourable
Meeting Date:
13/07/2022
Study Type:
CT application
Principal Investigator:
Dr Adrian Murphy
PI Institution:
Beaumont Hospital
Sponsor:
Seagen, Inc.